Here are a few brief analogies for Oragenics:

• It's like a very small, early-stage pharmaceutical company attempting to develop a wide range of drugs and vaccines, similar to a startup version of a diversified giant like Pfizer or Johnson & Johnson.
• Imagine a biotech startup trying to develop COVID vaccines (like Moderna), antibiotics (like Merck), and weight loss drugs (like Novo Nordisk) all at once, still in its early research and development phase.

• NT-CoV2-1: An intranasal vaccine candidate providing immunity from SARS-CoV-2.
• Terra CoV-2: An intramuscular vaccine candidate providing immunity from SARS-CoV-2.
• LPT3-04: A candidate product being developed for weight loss.
• SMaRT Replacement Therapy: A topical treatment designed to prevent dental carries.
• MU1140 and related homologs: Product candidates under development through a collaboration agreement.

Oragenics, Inc. (OGEN) is a development-stage biopharmaceutical company focused on the research and development of drug candidates, including vaccines, antibiotics, and other therapeutic treatments. Given its current stage of operations, it does not have major customers that purchase commercialized products in the traditional sense, either individuals or companies.

Instead, Oragenics' financial relationships and potential revenue streams primarily stem from licensing and collaboration agreements with other companies related to the development and commercialization of its product candidates. Based on the provided description, the companies with which Oragenics has notable agreements are:

• Noachis Terra Inc.
• Precigen, Inc. (Symbol: PGEN)
• ILH Holdings, Inc.

These entities serve as partners and licensees rather than direct purchasers of commercial products from Oragenics.

Noachis Terra Inc.

Janet Huffman
Chief Executive Officer & Chief Financial Officer

Ms. Huffman was appointed Chief Executive Officer of Oragenics, Inc. effective May 2, 2025, and continues to serve as Chief Financial Officer, a role she assumed on March 7, 2023. She previously served as the interim CEO starting in January 2025. Prior to joining Oragenics, Ms. Huffman served as Chief Financial Officer for TRxADE HEALTH, Inc., a Nasdaq-listed company. In 2019, she was a founding member and Chief Financial Officer of Banyan Pediatric Care Centers. She led Banyan's merger with Assisted 4 Living, Inc., which was later renamed Arboreta Healthcare Inc., and continued as CFO for the combined entity until February 2022. Her prior experience includes serving as Chief Financial Officer for Signature HomeNow, a home healthcare services company, and holding finance and operations leadership roles at Infinity Homecare and Family Home Health Services.

James P. Kelly, MA, MD, FAAN, FANA
Chief Medical Officer

Dr. Kelly is the Executive Director of the Marcus Institute for Brain Health (MIBH) and a Professor of Neurology at the University of Colorado Anschutz Medical Campus. The MIBH is a specialized program providing care for US military Veterans with persistent symptoms of traumatic brain injury. He also serves as the National Director of the Gary Sinise Foundation Avalon Network. Previously, he was the founding Director of the National Intrepid Center of Excellence (NICoE) at Walter Reed National Military Medical Center.

William “Frank” Peacock MD
Chief Clinical Officer

Dr. Peacock is the Vice Chair for Emergency Medicine Research at Baylor College of Medicine and a past Professor at the Cleveland Clinic Lerner College of Medicine. He is also the Principal Investigator of a trial for a company developing blood biomarkers for the identification of concussion in the emergency department.

Mark Gandolfo
Project Manager

Mr. Gandolfo joined Oragenics as a project manager in 2023. Prior to this, he transitioned into the biopharmaceutical industry in 2021 as a project manager at Odyssey Health, Inc., after working in a physical therapy clinic for four years.

The key risks for Oragenics (OGEN) are primarily centered around the challenging and capital-intensive nature of biotechnology drug development.

1. Clinical Trial Outcomes and Regulatory Approval Risk: As a clinical-stage biotechnology company, Oragenics' business success hinges on the successful development, clinical trial completion, and regulatory approval of its product candidates. The company is advancing several candidates, including ONP-002 for concussion (currently in a Phase IIa clinical trial in Australia) and intranasal and intramuscular COVID-19 vaccine candidates (NT-CoV2-1 and Terra CoV-2). There are inherent risks associated with clinical trial outcomes and the complex regulatory approval processes, where setbacks, delays, or outright rejections could significantly impact the company's prospects and share price.
2. Funding and Capital Needs Risk: Oragenics has historically incurred significant operating losses and currently reports no revenue, dedicating its resources to research and development and clinical trials. The company emphasizes an ongoing need to raise additional capital to fund its business strategy and advance its product candidates through costly later-stage clinical trials. Failure to secure sufficient funding, whether through dilutive equity offerings or other non-dilutive sources, poses a substantial risk to its continued operations and product development timelines.
3. Competition and Evolving Market Dynamics: Oragenics operates within a highly competitive biopharmaceutical sector. While its concussion treatment candidate, ONP-002, addresses an unmet medical need with no FDA-approved pharmacological treatments currently available, its COVID-19 vaccine candidates face an already established and rapidly evolving market. The market opportunity for COVID-19 vaccines is expected to shift, driven by the need for updated vaccines against new variants and for unvaccinated populations, indicating significant competition from established players. Intense competition could limit the potential market share and commercial success of Oragenics' candidates, even if they achieve regulatory approval.

The rapid and widespread adoption of highly effective GLP-1 agonist drugs (such as Wegovy by Novo Nordisk and Zepbound by Eli Lilly) represents a significant emerging threat to Oragenics' weight loss candidate, LPT3-04. These treatments, from major pharmaceutical companies with vast resources, have fundamentally redefined efficacy expectations in the weight loss market, creating a significantly higher barrier for any new entrant.

Oragenics' COVID-19 vaccine candidates (NT-CoV2-1 and Terra CoV-2) face an overwhelming emerging threat from the entrenched dominance of established pharmaceutical giants (e.g., Pfizer, Moderna, AstraZeneca, Johnson & Johnson). These companies have already secured widespread approval, distribution, and public adoption of their vaccines, and continue to adapt their offerings for new variants, making market entry and competitive differentiation extremely difficult for a new candidate.

Oragenics, Inc. (OGEN) operates in several distinct markets with its primary product candidates. The addressable markets for these products vary by region and projected growth:

• COVID-19 Vaccine Candidates (NT-CoV2-1 and Terra CoV-2): The global COVID-19 vaccine market was valued at USD 8.23 billion in 2025 and is projected to reach USD 15.35 billion by 2034. Another estimate placed the global COVID-19 vaccine market at USD 13.71 billion in 2025, with a projected contraction to USD 8.28 billion by 2030, reflecting a shift from emergency mass immunization to routine programs. The global COVID-19 vaccine market size is also expected to reach USD 5 billion by 2024. Separately, the global mRNA COVID-19 vaccine market was valued at USD 3.788 billion in 2024 and is projected to grow to USD 4.167 billion by 2032. The U.S. vaccines market, encompassing all types of vaccines, was valued at USD 34.37 billion in 2022 and is projected to reach USD 59.77 billion by 2034. North America is projected to dominate the global vaccine market.
• Weight Loss Candidate (LPT3-04): The global weight loss and weight management market was valued at approximately USD 224.27 billion in 2021 and is predicted to grow to about USD 405.4 billion by 2030. Other estimations for the global market include USD 296.8 billion in 2024, expected to reach USD 572.4 billion by 2033, and USD 165.5 billion in 2023, anticipated to reach USD 399.3 billion by 2032. In the U.S., the total weight loss market reached an estimated USD 90 billion in 2023. More specifically, the U.S. medical weight loss market more than tripled since 2019 to USD 33.8 billion in 2024. The U.S. weight management market size was estimated at USD 37.86 billion in 2023.
• Topical Treatment to Prevent Dental Caries (SMaRT Replacement Therapy): The global dental caries and endodontic sector is expected to reach a valuation of USD 71.6 billion by 2036, growing from USD 39.6 billion in 2026. The global dental caries treatment market size was valued at USD 7.65 billion in 2024 and is projected to reach approximately USD 12.11 billion by 2034. Focusing on prevention, the global dental preventive supplies market size is expected to be valued at USD 5.2 billion in 2026 and projected to reach USD 6.8 billion by 2033. Another source states the global dental preventive supplies market was estimated at USD 5.9 billion in 2024 and is expected to grow to USD 8.8 billion in 2034. North America leads the dental preventive supplies market with approximately a 36% share. The U.S. dental caries treatment market size surpassed USD 2.69 billion in 2024 and is expected to be worth around USD 4.34 billion by 2034.
• Antibiotic Development (MU1140 and related homologs): The global antibiotics market is projected to reach USD 80.0 billion by 2035, from a valuation of USD 55.35 billion in 2025. Another report states the antibiotics market size is valued to increase by USD 18.22 billion, at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2029. North America accounts for a significant share of the global antibiotics market. The U.S. antibiotic resistance market alone was valued at USD 3.7 billion in 2025.

1. Advancement and Potential Commercialization of ONP-002 for Concussion and Mild Traumatic Brain Injury (mTBI): Oragenics' lead candidate, ONP-002, is an intranasal neurosteroid progressing through clinical trials as a potential first-in-class pharmacological treatment for concussion and mTBI. The company has initiated Phase IIa clinical trials for ONP-002 in Australia, with U.S. Phase IIb trials planned to follow. This represents a significant market opportunity, with the global concussion market projected to reach $9 billion. Successful development and regulatory approval of ONP-002 would be a primary source of future revenue, potentially through direct sales or licensing agreements.
2. Expansion of the Proprietary Intranasal Delivery Platform to Other Neurological Conditions: Beyond ONP-002, Oragenics aims to leverage its intranasal drug delivery technology for a broader pipeline of therapeutics targeting various neurological conditions. The company's platform is designed for rapid and non-invasive drug delivery directly to the brain, which has potential applications across disorders such as Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. This strategic positioning as a platform technology leader in intranasal neurological pharmaceuticals is expected to open multiple high-demand market sectors.
3. Strategic Acquisitions of Additional Central Nervous System (CNS) Assets: Oragenics is actively exploring potential acquisitions of new CNS assets focused on brain health, brain recovery, and neuroprotection. This initiative aims to build a diversified CNS pipeline that complements its existing programs and proprietary intranasal delivery platform. These acquisitions could accelerate pipeline development and broaden the company's therapeutic offerings, contributing to future revenue streams.
4. Strategic Partnerships and Licensing Agreements: As a clinical-stage biotechnology company, Oragenics' future revenue growth will likely be driven by forming strategic partnerships and entering into licensing agreements for the development, marketing, and sales of its product candidates, especially ONP-002. The company intends to pursue such agreements with experienced sales organizations upon regulatory approval. Collaborations, such as the existing AI-enabled drug discovery partnership with Receptor.AI, are also crucial for accelerating pipeline development and identifying new therapeutic applications.

Share Issuance

• Oragenics completed a private placement in August 2023, issuing 404,728 shares of common stock and 404,728 shares of Series E Mirroring Preferred Stock, raising approximately $840,000.
• In Q1 2025, the company raised approximately $2.6 million through at-the-market (ATM) equity sales.
• Oragenics successfully closed a public offering in July 2025, generating approximately $16.5 million in gross proceeds from the issuance of Series H Convertible Preferred Stock and Warrants.

Inbound Investments

• Two healthcare-focused investors provided approximately $840,000 in gross proceeds through a private placement in August 2023.
• The company secured approximately $5 million in new funding in Q1 2025, which included $2.6 million from ATM equity sales and $2.25 million in non-dilutive debt financing.
• A public offering of Series H Convertible Preferred Stock and Warrants in July 2025 resulted in approximately $16.5 million in gross proceeds, primarily intended to advance clinical development.

Outbound Investments

• In December 2023, Oragenics completed the acquisition of assets from Odyssey Health, Inc., related to neurological drug therapies, by paying $1,000,000 in cash and issuing 8,000,000 shares of convertible Series F Preferred Stock.
• As of March 2026, Oragenics is exploring potential acquisitions of additional central nervous system assets focused on brain health and recovery indications to expand its pipeline.

Capital Expenditures

• Proceeds from the July 2025 public offering are allocated to advance the clinical development of ONP-002, support other research and development activities, and strengthen manufacturing and regulatory capabilities.
• Oragenics has engaged Sterling Pharma Solutions for cGMP manufacturing at their Cary, North Carolina facility, indicating investment in manufacturing services to support its clinical programs.